Cepheid Inc., of Sunnyvale, Calif., appointed William McMillan vice president of biotechnology.
Cholestech Corp., of Hayward, Calif., appointed Michael Casey to its board.
Endovasc Ltd., of Montgomery, Texas, added Martin Leon and Daniel Burkhoff to its scientific advisory board.
Forbes Medi-Tech Inc., of Vancouver, British Columbia, appointed Don MacDonald chief financial officer.
Genmab A/S, of Copenhagen, Denmark, named Ole Baadsgaard medical director and Rinette Andreasen a new project manager.
Hematech LLC, of Westport, Conn., appointed James Robl as president and chief scientific officer.
Impax Laboratories Inc., of Hayward, Calif., named David Doll senior vice president, sales and marketing, effective March 4.
Luminex Corp., of Austin, Texas, appointed Thomas Caskey to its board.
MedImmune Inc., of Gaithersburg, Md., appointed Gregory Patrick senior vice president and chief financial officer.
Pharmacopeia Inc., of Princeton, N.J., promoted Michael Stapleton to executive vice president and chief operating officer for its software business and Stephen Spearman to executive vice president and chief operating officer of its drug discovery business.
Pheromone Sciences Corp., of Toronto, appointed Eldon Smith to its board.
Quintiles Transnational Corp., of Research Triangle Park, N.C., appointed Joseph Phillips vice president, pharmaceutical operations in its Quintiles Consulting group.
Regeneron Pharmaceuticals Inc., of Tarrytown, New York, named George Yancopoulos president, Regeneron Research Laboratories, chief scientific officer and executive vice president. It also appointed Murray Goldberg senior vice president, finance and administration, chief financial officer, treasurer, and assistant secretary; Randall Rupp senior vice president, manufacturing and process sciences; and Neil Stahl senior vice president, preclinical development and biomolecular science. It made the following vice president appointments: Ann Acheson to VP, product development operations and logistics; Kevin Bailey to VP, preclinical manufacturing and process development; Thomas Daly to VP, protein chemistry sciences; James Fandl to VP, protein expression sciences; David Glass to VP, muscle program and technology development; Andrew Murphy to VP, gene discovery and bioinformatics; and Stanley Wiegand to VP, neural endocrine and obesity research.